Clinical trial
Sorafenib in Treating Patients With Advanced Solid Tumors
NCT00436579 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00436579 |
|---|---|
| Title | Sorafenib in Treating Patients With Advanced Solid Tumors |
| Official title | A Dose Escalation Study of Sorafenib (BAY 43-9006, NSC 724772) in Nomotensive Patients With Advanced Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other, Procedure |
| Interventions | sorafenib tosylate, pharmacological study, assessment of therapy complications, laboratory biomarker analysis |
| Enrollment | 110 |
| Start date | Jan 1, 2007 |
| Primary completion | Sep 1, 2011 |
| First posted | Feb 19, 2007 |
| Last update posted | Feb 24, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: